Edwin Lin, MD, PhD, discusses the utilization of antibody-drug conjugates and the importance of defining biomarker-based approaches for this treatment class in patients with non–small cell lung cancer.
Edwin Lin, MD, PhD
Advertisement
Articles by Edwin Lin, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5